NDRG4 and small cell lung carcinoma: SCLC patients with NDRG4 mutations are more sensitive to chemotherapy and have a longer survival time than those without such mutations, which suggests that the NDRG4 protein could be used as a biomarker to predict the clinical prognosis of SCLC.